SES
2.4.2020 15:16:08 CEST | Business Wire | Press release
SES S.A. held its Annual General Meeting (AGM) today in Betzdorf, Luxembourg, in which all resolutions were approved by shareholders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200402005503/en/
The meeting was held based on the rules set out in the Grand Ducal Regulation of 20 March 2020 with shareholders participating remotely by appointing SES designated proxyholders to represent them at the meeting and to carry out their voting instructions given ahead of the meeting. Compliance with voting instructions was verified by the bureau of the AGM.
The approved resolutions included the company's 2019 financial accounts and the proposed dividend of EUR 0.40 per A-share which will be paid to shareholders on 23 April 2020. Accordingly, SES’s 2019 Annual Report has been published and is available to download at http://www.ses.com/annual-report .
Shareholders also approved a reduction in Board size from 14 to 12 Directors.
In addition, shareholders elected Béatrice de Clermont-Tonnerre and Peter van Bommel for an initial two-year mandate and elected Paul Konsbruck and Frank Esser for another three-year mandate. They also re-elected Ramu Potarazu, Kaj-Erik Relander and Anne-Catherine Ries for three years.
In the context of the reduction in Board size, shareholders also noted the resignations of Victor Casier, Hadelin de Liedekerke Beaufort, Marc Serres and François Tesch as Directors of SES. The AGM thanked those Directors for their contributions.
Consequently, the Board is now composed as follows: A-shareholders are represented by (all of them independent) Romain Bausch, Béatrice de Clermont-Tonnerre, Frank Esser, Tsega Gebreyes, Ramu Potarazu, Kaj-Erik Relander, Peter van Bommel, Katrin Wehr-Seiter; and B-shareholders are represented by Serge Allegrezza, Paul Konsbruck, Anne-Catherine Ries, Françoise Thoma.
At the AGM, Romain Bausch, Chairman of the SES Board and former President and CEO, informed the shareholders that he would not seek a new mandate as Chairman. Mr Bausch will remain on the Board as an independent Director.
Accordingly, in its meeting following the AGM, the Board of Directors elected Frank Esser as Chairperson of the Board for a period of one year and re-elected both Tsega Gebreyes and Anne-Catherine Ries as Vice-Chairpersons of the Board, also for a period of one year.
“Having been at the helm of the company for 25 years, firstly as CEO and latterly as Chairman and with the company now entering an exciting period of transformation under Steve Collar’s leadership and with a newly invigorated and streamlined Board, I consider it to be the right time to pass the baton to a new Chair in the renewed Board,” said Romain Bausch. “It has been a true privilege to serve SES in these different roles and I want to thank our shareholders for their continued support.”
“I am honoured to be elected Chairperson at this important and exciting time for our company with SES being in a great position for further development,” said Frank Esser. “I am delighted to be joining the Board with several new Directors who will each bring strong competencies, complementing those of the rest of our Board colleagues. I would also like to take this opportunity to pay tribute to Romain and his contribution, commitment and on-going service to SES with his continued presence as a Director.”
Follow us on:
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of over 365 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005503/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping11.8.2026 07:00:00 CEST | Press release
Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1 Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3 It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4 Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3 This press release features multimedia. View the
Stonebranch is Again Named a Leader in the 2026 Gartner® Magic Quadrant™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 17:00:00 CEST | Press release
Gartner recognizes Stonebranch as a Leader for the third consecutive year based on Completeness of Vision and Ability to Execute. Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build
Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 16:09:00 CEST | Press release
New facility in Cummings Research Park brings engineering closer to customers while advancing mission processing technologies and strengthening Frontgrade's long-term investment in Huntsville Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboratio
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 15:00:00 CEST | Press release
Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized autho
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release
Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
